Alzheimer’s disease is the most common form of dementia and affects millions of people worldwide. It is a progressive brain disorder that slowly damages memory, thinking skills, and the ability to carry out daily activities.
As the disease advances, people may struggle to recognize family members, communicate with others, or live independently. The condition places a heavy emotional and financial burden on patients, families, and healthcare systems around the world.
Despite decades of research, there is still no cure for Alzheimer’s disease. Current treatments can help manage symptoms for a period of time, but they cannot stop the disease from progressing. Because of this, scientists continue searching for new ways to slow down or prevent the damage that occurs in the brain.
One of the main features of Alzheimer’s disease is the buildup of a protein called amyloid beta. This protein can stick together and form clumps known as plaques.
These plaques accumulate between brain cells and are believed to play an important role in damaging neurons and disrupting communication within the brain. Over time, this damage contributes to memory loss and cognitive decline.
In recent years, researchers have developed antibody-based drugs that target amyloid beta. These treatments have provided some hope, but they also have limitations. They are often very expensive, may not be available to everyone, and can sometimes cause serious side effects. As a result, scientists are continuing to explore simpler and safer approaches.
A new study published in the journal Neurochemistry International has identified a surprising candidate that may help. Researchers from Kindai University in Japan and their collaborators found that arginine, a naturally occurring amino acid, may reduce the harmful buildup of amyloid beta in the brain.
Arginine is already well known to scientists and doctors. It is found naturally in many foods, including meat, fish, dairy products, nuts, and seeds.
The body also uses arginine for several important functions, including supporting blood flow, helping wounds heal, and maintaining a healthy immune system. It is widely available as a dietary supplement and has been used safely by many people for years.
The research team was led by graduate student Kanako Fujii and Professor Yoshitaka Nagai from the Department of Neurology at Kindai University, together with Associate Professor Toshihide Takeuchi from the university’s Life Science Research Institute.
Their goal was to investigate whether arginine could interfere with the harmful processes involved in Alzheimer’s disease.
The researchers first carried out laboratory experiments using solutions that contained amyloid beta proteins. They discovered that when arginine was added, the proteins were much less likely to stick together and form clumps.
The higher the concentration of arginine, the stronger this protective effect became. This suggested that arginine directly interferes with the process that leads to amyloid plaque formation.
After seeing encouraging results in the laboratory, the scientists tested arginine in animal models of Alzheimer’s disease. They used genetically modified fruit flies that produced a toxic form of amyloid beta and mice that carried genetic changes linked to Alzheimer’s disease in humans.
These animal models are commonly used because they develop many of the same brain abnormalities seen in patients.
The results were encouraging. In both fruit flies and mice, treatment with oral arginine reduced the buildup of amyloid beta. In the mice, the amount of amyloid plaque found in the brain was significantly lower than in untreated animals.
The researchers also found lower levels of a particularly harmful form of amyloid beta known as insoluble Aβ42. This form is considered especially toxic because it is more likely to form plaques and damage brain cells.
Perhaps even more importantly, the mice that received arginine performed better on tests that measured learning and memory. These findings suggest that the reduction in amyloid buildup may have helped protect brain function.
The benefits were not limited to amyloid reduction. The researchers also observed lower levels of inflammatory signals in the brains of treated mice.
Brain inflammation is another key feature of Alzheimer’s disease and can contribute to further damage of nerve cells. By reducing both amyloid accumulation and inflammation, arginine appeared to provide multiple layers of protection.
Professor Nagai noted that one of the most attractive aspects of arginine is its established safety record. Unlike many experimental drugs, arginine has already been used by humans and is relatively inexpensive.
Because it is already approved for medical use in Japan and can enter the brain, researchers may be able to move toward human clinical trials more quickly than would be possible with an entirely new drug.
The study also highlights the growing interest in a strategy known as drug repositioning. This approach involves finding new uses for substances that are already known to be safe. Because much of the safety testing has already been completed, researchers can often save significant time and resources compared with developing a new drug from scratch.
The scientists emphasized that the specific doses used in their experiments are not the same as those found in commercial supplements. People should not assume that taking arginine supplements will prevent or treat Alzheimer’s disease. Much more research is needed before any recommendations can be made for patients.
Still, the findings provide an important proof of concept. The study shows that a simple and naturally occurring compound can reduce harmful protein buildup, decrease inflammation, and improve memory-related performance in animal models of Alzheimer’s disease.
Future studies will need to determine whether these benefits can be reproduced in humans. Clinical trials will also be necessary to identify the safest and most effective doses. However, the results offer hope that future Alzheimer’s treatments may not rely solely on complex and costly medications.
Instead, some therapies may come from affordable compounds that are already familiar to scientists and doctors. For the millions of families affected by Alzheimer’s disease, that possibility represents an encouraging step forward in the search for better treatments.
If you care about Alzheimer’s, please read studies about Vitamin D deficiency linked to Alzheimer’s, vascular dementia, and Oral cannabis extract may help reduce Alzheimer’s symptoms.
For more information about brain health, please see recent studies about Vitamin B9 deficiency linked to higher dementia risk, and results showing flavonoid-rich foods could improve survival in Parkinson’s disease.
The study was published in Neurochemistry International.
Copyright © 2026 Knowridge Science Report. All rights reserved.
